MDTH, AVOT, NVDA, PWRM, OPTR - Stock Highlights From DrStockPick.com!

American Video Teleconferencing Corp. (Pink Sheets:AVOT) is pleased to announce that it has hired a French speaking geologist to search the archives of the Quebec Department of Mines for Rare Earths showings not on a current computer file. The company believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings. As neither the Federal nor Quebec Governments have carried out any air borne surveys in this area, the company will seek a contractor to do an air borne Mag-EM radiometric survey. This survey will cover its present holdings and the immediate surrounding area looking for future acquisitions. American Video is pleased to be working in the Province of Quebec as it is rated the number one jurisdiction in the world to carry out mineral exploration. The Quebec Government gives a rebate up to 45% for property expenditures.

China is the world’s major producer of rare earth elements, many are used in today’s technology, such as new energy sources and hybrid cars. China announced in July that it will slash exports for minerals used to make hybrid cars and televisions.

The nation has begun to drastically restrict the exports of rare-earth materials, which frequently find use in “green” technology designs, which includes hybrid vehicles and energy-efficient lighting, also in the medical, defense, and consumer markets. The country delivers nearly 100% of the world’s rare-earth materials: 17 metals which can be hard to refine and that also often occur in alike ore deposits. The cutbacks have resulted in shock waves throughout the electronics industry and might force design changes in the longer term.

Constraints on Chinese exports are forming opportunities for non-Chinese projects.

American Video will aggressively continue to search world-wide for opportunities in Precious, Base and Rare Earths metal projects.

*****************************************

Power3 Medical Products, Inc. (OTC.BB:PWRM) is a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

Power3’s management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few

Because early breast cancer is asymptomatic, the only way to detect it is through screening. Mammography is currently the widely accepted method for breast cancer screening. However, most women who have an abnormal mammogram do not have cancer.

Mammography often leads to identification of a “probably benign” lesion or an uninformative mammography. Clinicians may be reluctant to refer such a patient for a biopsy; they may also reluctant to do nothing. Often such patients are referred for frequent repeat mammography examinations.

The availability of an accurate and non-invasive test would avoid such repeated mammogram exams, with their attendant discomfort, inconvenience, x-ray exposure, and emotional stress. In such cases, Power3's BC-SeraPro™ with 80% sensitivity and 87% specificity, could exclude malignancy at higher accuracy than mammography.

PWRM’s BC-SeraPro™ is then an ideal diagnostic test to evaluate breast cancer abnormalities found by mammogram or breast examination. The test would distinguish women who should have a biopsy from those who can safely avoid one. BC-SeraPro™ could detect the disease at a point when treatment is more effective, less expensive, or both.

*****************************************

Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced that fidaxomicin, the Company's lead product candidate, has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of pediatric Clostridium difficile infection (CDI). This orphan drug designation applies to the active moiety and covers all formulations of fidaxomicin used to treat Clostridium difficile infection in children 16 years of age or younger. Optimer has completed Phase 3 trials in adults and filed applications in the U.S. and the EU for marketing authorization for fidaxomicin for the treatment of CDI and for the prevention of recurrences.

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. It develops products that treat gastrointestinal infections and related diseases.

*****************************************

NVIDIA Corporation (Nasdaq:NVDA) announced a partnership that puts NVIDIA GPUs in navigation and vehicle-information systems across all next-generation BMW cars worldwide. NVIDIA GPUs will power BMW's in-car navigation systems to deliver vivid graphics with detailed terrain models, landmarks and a stunning new interface. NVIDIA processors will be found throughout BMW's range of models, including the 7-Series, 5-Series, 3-Series, Mini Cooper line and X-Series of sports activity vehicles.

Nvidia Corporation provides visual computing technologies that generate interactive graphics on workstations, personal computers, game consoles, and mobile devices. It operates in four segments: Graphic Processing Unit (GPU), Professional Solutions Business (PSB), Media and Communications Processor (MCP), and Consumer Products Business (CPB).

*****************************************

MedCath Corp. (Nasdaq:MDTH) announced the completion of the sale of substantially all the assets of TexSan Heart Hospital, owned by MedCath and its physician investors, to Methodist Healthcare System of San Antonio. The transaction, which was announced in November, and was subject to customary closing conditions and regulatory requirements, was completed effective. This is MedCath's fifth completed transaction since announcing in March it had formed a Strategic Options Committee to consider the sale either of the entire company or its assets.

MedCath Corporation, together with its subsidiaries, engages in the ownership and operation of hospitals in partnership with physicians in the United States. The company focuses primarily on providing acuity services, including the diagnosis and treatment of cardiovascular disease.

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTC:AVOT) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.

Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).